<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00777855</url>
  </required_header>
  <id_info>
    <org_study_id>warfarin-6006</org_study_id>
    <nct_id>NCT00777855</nct_id>
  </id_info>
  <brief_title>Drug Interaction Study of Rifampin and Warfarin in Healthy Volunteers.</brief_title>
  <official_title>The Effects of Rifampin on the Pharmacokinetics of Warfarin in Healthy Volunteers.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the importance of uptake drug transporters in the
      drug disposition of warfarin. We predict that the elimination of warfarin will be decreased
      when co-dosed with an inhibitor of uptake drug transporters.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>S- and R- Enantiomers of Warfarin (S-warfarin and R-warfarin) Area Under the Plasma Concentration-time Curve (AUC) From 0 to 12 Hours.</measure>
    <time_frame>0-12 hours after warfarin dosing</time_frame>
    <description>Uptake effects on warfarin pharmacokinetics during time period of hepatic organic anion-transporting polypeptide (OATP) inhibition by rifampin. Blood collection 1, 2, 4, 6, 8, and 12 hours after warfarin dosing.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve From Time Zero to Infinity of S-warfarin and R-warfarin</measure>
    <time_frame>0-120 hours after warfarin dosing</time_frame>
    <description>Analysis of all concentration-time data. Blood collection 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, and 120 hours after warfarin dosing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of S-warfarin and R-warfarin</measure>
    <time_frame>0-120 hours after warfarin dosing</time_frame>
    <description>Blood collection 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, and 120 hours after warfarin dosing.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>warfarin then warfarin plus rifampin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>warfarin plus rifampin</intervention_name>
    <description>warfarin 7.5mg po x 1; rifampin 600mg IV x 1</description>
    <arm_group_label>warfarin then warfarin plus rifampin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>warfarin</intervention_name>
    <description>warfarin 7.5mg po x 1</description>
    <arm_group_label>warfarin then warfarin plus rifampin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female 18-60 years of age;

          -  Healthy adult with no active medical problems or significant chronic diseases as
             determined by the study doctor based on history, physical exam and laboratory
             evaluations;

          -  BMI between 18.5 - 30 kg/m2;

          -  Taking no medications 2 weeks before and during the study enrollment, including drugs
             of abuse, prescription or over-the-counter (OTC) medications (except acetaminophen);

          -  Subjects able to maintain adequate birth control during the study independent of
             hormonal contraceptive use;

          -  Be able to provide written informed consent and comply with requirements of the study;

          -  Avoid eating grapefruit and drinking grapefruit juice from 7 days before the first
             study day until completion of the entire study;

          -  Abstinence from alcoholic beverages, caffeinated beverages and orange juice from 6pm
             the night before a study day until completion of that study day;

          -  Avoidance of contact sports and/or other activities with significant risk of trauma
             injury for 7 days after each study day.

          -  Fast from food and beverages at least 8 hours prior to medication dosing;

          -  Be able to read, speak and understand English

        Exclusion Criteria:

          -  Subjects on prescription or chronic over-the counter medications (including hormonal
             contraceptives);

          -  Subjects with known allergy to warfarin and/or rifampin;

          -  Subjects who are not homozygous for cytochrome P450 2C9 (CYP2C9 *1) (known poor
             metabolizers).

          -  Subjects with a history or diagnosis of hemorrhagic tendencies or blood dyscrasias;

          -  Subjects with liver failure or liver function test (LFT) results &gt;2x upper limit of
             normal;

          -  Subjects with clinically significant elevations in international normalized ratio
             (INR), prothrombin (PT), prothrombin time (PTT), serum creatinine (SCr), blood urea
             nitrogen (BUN) or other screening laboratory tests as determined by study physician;

          -  Subjects with Hct &lt;30 mg/dL;

          -  Subjects with history of GI bleed or peptic ulcer disease;

          -  Subjects with a recent history of trauma;

          -  Subjects with a recent history of or upcoming plan of surgery;

          -  Subjects who smoke tobacco;

          -  Subjects with ongoing alcohol or illegal drug use;

          -  Subjects who are pregnant, lactating or attempting to conceive;

          -  Subjects unable to maintain adequate birth control during the study;

          -  Subjects unable to follow protocol instructions or protocol criteria.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leslie Z Benet, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSF Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 20, 2008</study_first_submitted>
  <study_first_submitted_qc>October 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 22, 2008</study_first_posted>
  <results_first_submitted>January 14, 2013</results_first_submitted>
  <results_first_submitted_qc>May 8, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 17, 2013</results_first_posted>
  <last_update_submitted>May 8, 2013</last_update_submitted>
  <last_update_submitted_qc>May 8, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 17, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>warfarin</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>drug transporter</keyword>
  <keyword>healthy volunteer</keyword>
  <keyword>drug interaction</keyword>
  <keyword>rifampin</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warfarin</mesh_term>
    <mesh_term>Rifampin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Healthy non-smoking volunteers from community</recruitment_details>
      <pre_assignment_details>All participants were medication free throughout study enrollment</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Warfarin First, Then Warfarin+Rifampin</title>
          <description>In a randomized, single-dose, two-period, crossover design, 5 participants received warfarin alone 7.5mg po; after a minimum of 14 days, participants received a 30-minute IV infusion of 600mg rifampin immediately followed by warfarin 7.5mg po.</description>
        </group>
        <group group_id="P2">
          <title>Warfarin+Rifampin First, Then Warfarin Alone</title>
          <description>In a randomized, single-dose, two-period, crossover design, 5 participants received a 30-minute IV infusion of 600mg rifampin immediately followed by warfarin 7.5mg po; after a minimum of 14 days, participants received warfarin alone 7.5mg po.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout Period (&gt;= 14 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Entire Study Population</title>
          <description>Includes participants randomized to receive warfarin alone then warfarin+rifampin, and those randomized to receive warfarin+rifampin then warfarin alone in the crossover design</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.1" spread="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>S- and R- Enantiomers of Warfarin (S-warfarin and R-warfarin) Area Under the Plasma Concentration-time Curve (AUC) From 0 to 12 Hours.</title>
        <description>Uptake effects on warfarin pharmacokinetics during time period of hepatic organic anion-transporting polypeptide (OATP) inhibition by rifampin. Blood collection 1, 2, 4, 6, 8, and 12 hours after warfarin dosing.</description>
        <time_frame>0-12 hours after warfarin dosing</time_frame>
        <population>Each of 10 participants received both treatments separated by a minimum of 14 days; treatment sequence was randomly assigned</population>
        <group_list>
          <group group_id="O1">
            <title>Warfarin</title>
            <description>warfarin : warfarin 7.5mg po x 1</description>
          </group>
          <group group_id="O2">
            <title>Warfarin Plus Rifampin</title>
            <description>warfarin plus rifampin : warfarin 7.5mg po x 1 immediately following rifampin 600mg IV x 1</description>
          </group>
        </group_list>
        <measure>
          <title>S- and R- Enantiomers of Warfarin (S-warfarin and R-warfarin) Area Under the Plasma Concentration-time Curve (AUC) From 0 to 12 Hours.</title>
          <description>Uptake effects on warfarin pharmacokinetics during time period of hepatic organic anion-transporting polypeptide (OATP) inhibition by rifampin. Blood collection 1, 2, 4, 6, 8, and 12 hours after warfarin dosing.</description>
          <population>Each of 10 participants received both treatments separated by a minimum of 14 days; treatment sequence was randomly assigned</population>
          <units>ng/ml*h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC (0-12 hours) of S-warfarin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2,250" spread="340"/>
                    <measurement group_id="O2" value="2,230" spread="460"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC (0-12 hours) of R-warfarin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2,850" spread="460"/>
                    <measurement group_id="O2" value="2,930" spread="510"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Concentration-time Curve From Time Zero to Infinity of S-warfarin and R-warfarin</title>
        <description>Analysis of all concentration-time data. Blood collection 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, and 120 hours after warfarin dosing.</description>
        <time_frame>0-120 hours after warfarin dosing</time_frame>
        <population>Each of 10 participants received both treatments, in randomly assigned order, separated by a minimum of 14 days</population>
        <group_list>
          <group group_id="O1">
            <title>Warfarin</title>
            <description>warfarin : warfarin 7.5mg po x 1</description>
          </group>
          <group group_id="O2">
            <title>Warfarin Plus Rifampin</title>
            <description>warfarin plus rifampin : warfarin 7.5mg po x 1 immediately following rifampin 600mg IV x 1</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-time Curve From Time Zero to Infinity of S-warfarin and R-warfarin</title>
          <description>Analysis of all concentration-time data. Blood collection 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, and 120 hours after warfarin dosing.</description>
          <population>Each of 10 participants received both treatments, in randomly assigned order, separated by a minimum of 14 days</population>
          <units>ng/ml*h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC(0-infinity) of S-warfarin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8,420" spread="1,090"/>
                    <measurement group_id="O2" value="7,410" spread="2,500"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC(0-infinity) of R-warfarin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18,600" spread="3,400"/>
                    <measurement group_id="O2" value="14,100" spread="4,100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Plasma Concentration (Cmax) of S-warfarin and R-warfarin</title>
        <description>Blood collection 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, and 120 hours after warfarin dosing.</description>
        <time_frame>0-120 hours after warfarin dosing</time_frame>
        <population>Each of 10 participants received both treatments, in randomly assigned order, separated by a minimum of 14 days</population>
        <group_list>
          <group group_id="O1">
            <title>Warfarin</title>
            <description>warfarin : warfarin 7.5mg po x 1</description>
          </group>
          <group group_id="O2">
            <title>Warfarin Plus Rifampin</title>
            <description>warfarin plus rifampin : warfarin 7.5mg po x 1 immediately following rifampin 600mg IV x 1</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentration (Cmax) of S-warfarin and R-warfarin</title>
          <description>Blood collection 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, and 120 hours after warfarin dosing.</description>
          <population>Each of 10 participants received both treatments, in randomly assigned order, separated by a minimum of 14 days</population>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cmax of S-warfarin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="329" spread="70"/>
                    <measurement group_id="O2" value="303" spread="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax of R-warfarin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="375" spread="116"/>
                    <measurement group_id="O2" value="351" spread="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>120 hours after warfarin dosing</time_frame>
      <desc>Each of 10 participants received 2 treatments (warfarin, with or without rifampin), in randomly assigned order, separated by a minimum of 14 days. Participants presented for venous blood collection and were assessed for adverse events at 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, and 120 hours after warfarin dosing.</desc>
      <group_list>
        <group group_id="E1">
          <title>Entire Study Population</title>
          <description>Each of 10 participants received both study treatments, in randomly assigned sequence, separated by a minimum of 14 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Leslie Benet</name_or_title>
      <organization>UCSF</organization>
      <phone>(415) 476-3853</phone>
      <email>leslie.benet@ucsf.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

